Hercules Capital

Semperis develops an identity‑focused cybersecurity platform that protects the integrity and availability of enterprise directory services. Its suite enables organizations to automatically restore an entire Active Directory forest, recover thousands of objects or individual attributes, and revert to a previous state after accidental or malicious changes. The platform also offers real‑time attribute search, comparison, and restoration, hybrid threat detection, incident response, disaster recovery, and tools for Active Directory migration and consolidation. Additional capabilities include security posture assessment and attack path discovery within an identity resilience framework. Founded in 2013–2014, the company is headquartered in Hoboken, New Jersey, with offices in New York and Ramat Gan, and serves Fortune 500, financial, healthcare, and government customers worldwide.

Provention Bio, Inc. is a clinical-stage biopharmaceutical company based in Oldwick, New Jersey, focused on developing and commercializing innovative therapeutics aimed at intercepting and preventing immune-mediated diseases. The company's pipeline includes several product candidates, such as PRV-031 teplizumab, which is in Phase III trials for the interception of type 1 diabetes, and PRV-6527, an oral CSF-1R inhibitor currently in Phase IIa trials for Crohn's disease. Additional candidates include PRV-3279 for lupus, PRV-101, a vaccine for coxsackie virus B infections, and PRV-015, an anti-IL-15 monoclonal antibody in Phase IIb trials for non-responsive celiac disease. Provention Bio's approach aims to reduce the burden of chronic autoimmune and inflammatory diseases through early intervention. The company was incorporated in 2016 and is committed to leveraging its expertise in translational medicine and immunology to efficiently develop and partner with clinical-stage assets.

SCYNEXIS, Inc. is a biotechnology company focused on developing therapies for fungal infections in the United States and internationally. Its lead product candidate, ibrexafungerp, is being developed as both an oral and intravenous treatment for various fungal infections, including vulvovaginal candidiasis and invasive aspergillosis. Ibrexafungerp has successfully completed Phase 2 clinical trials for its indication in vulvovaginal candidiasis. The company collaborates with Merck Sharp & Dohme Corp. and R-Pharm, CJSC to advance the development and commercialization of ibrexafungerp. In addition to its antifungal focus, SCYNEXIS engages in drug discovery and development across multiple therapeutic areas, including antibacterials and oncology, and offers contract research solutions such as medicinal chemistry and process development. Originally founded in 1999 and known as SCYNEXIS Chemistry & Automation, Inc., the company rebranded to SCYNEXIS, Inc. in June 2002 and is headquartered in Jersey City, New Jersey.

Antares Pharma, Inc. is a specialty pharmaceutical company dedicated to developing and commercializing self-administered parenteral products and technologies. Founded in 1978 and headquartered in Ewing, New Jersey, the company offers a range of injection products designed to improve patient compliance and safety. Notable products include OTREXUP, a pre-filled syringe for administering methotrexate to patients with rheumatoid arthritis and psoriasis, and XYOSTED, which treats testosterone deficiency in adult males. Antares Pharma also produces Sumatriptan Injection for migraines, Epinephrine Injection for anaphylaxis, and Makena auto injectors to mitigate preterm birth risks. The company's innovative platforms include Vibex disposable auto-injectors and Vision reusable needle-free injectors, enhancing the self-injection experience. Through strategic alliances with prominent pharmaceutical companies, Antares Pharma continues to expand its portfolio of self-injection technologies and improve treatment options for patients across various medical conditions.

Aprecia Pharmaceuticals, LLC is a pharmaceutical company specializing in the development and manufacturing of innovative drug delivery systems. Founded in 2003, the company is headquartered in Blue Ash, Ohio, and operates manufacturing facilities in East Windsor and New Jersey. Aprecia is known for its ZipDose technology, which enables orodispersible formulations of medications, making it easier for patients to take their prescribed drugs. The company’s product portfolio includes SPRITAM, an oral tablet formulation of levetiracetam designed to treat various seizure types. Additionally, Aprecia offers CustomRelease for diverse time-release profiles, NanoDose for submilligram dosing, and ImplantaDose for post-surgical management. Through its advanced technologies, Aprecia Pharmaceuticals aims to enhance patient compliance and improve therapeutic outcomes.

Flowonix Medical, Inc. is a medical device company focused on developing implantable drug delivery systems to address chronic neurological disorders. The company specializes in creating devices that facilitate the precise infusion of therapeutic drugs directly into the spine, thereby enhancing treatment efficacy for patients experiencing long-term pain. Its product lineup includes the Prometra drug delivery system, which administers Infumorph, a medication designed for pain management, along with the Prometra Pump and a catheter that aids in the accurate placement of medication within the intrathecal space. Established in 2005 and headquartered in Mount Olive, New Jersey, Flowonix also maintains an office in Mansfield, Massachusetts, and is committed to improving patients' quality of life through innovative technology and reliable medical solutions.

Agile Therapeutics, Inc. is a women's healthcare company based in Princeton, New Jersey, dedicated to the research, development, and commercialization of prescription contraceptive products. The company's lead product is Twirla, a once-weekly transdermal contraceptive patch that combines levonorgestrel and ethinyl estradiol, designed to provide a non-daily option for contraception. Agile Therapeutics is also advancing a pipeline of additional products and extensions related to Twirla, including regimens aimed at offering women extended cycles, shorter and lighter periods, and a progestin-only patch for those who cannot or prefer not to use estrogen. Utilizing proprietary Skinfusion technology, the company aims to deliver effective contraceptive solutions that address the unmet health needs of women today. Founded in 1997, Agile Therapeutics continues to focus on innovating women's healthcare options.

Melinta Therapeutics is a pharmaceutical company dedicated to discovering, developing, and commercializing novel antibiotics to combat drug-resistant infections. Its portfolio includes Baxdela, Vabomere, Orbactiv, and Minocin, treating various bacterial infectious diseases. The company's mission is driven by the urgent need for new therapies against antibiotic-resistant pathogens.

ADMA Biologics, Inc. is a biopharmaceutical company focused on developing, manufacturing, and marketing specialty plasma-derived biologics aimed at treating immune deficiencies and infectious diseases in the United States. The company offers a range of products, including BIVIGAM and ASCENIV, both intravenous immune globulin therapies for primary humoral immunodeficiency, as well as Nabi-HB, which is used for acute exposure to Hepatitis B. ADMA is also involved in the development of additional plasma-derived therapeutics, particularly targeting infections like S. pneumonia. To support its operations, the company runs FDA-licensed source plasma collection facilities known as ADMA BioCenters, which contribute to the supply of plasma necessary for its product manufacturing. ADMA Biologics distributes its products through independent distributors, sales agents, specialty pharmacies, and other healthcare providers. Founded in 2004 and based in Ramsey, New Jersey, ADMA is dedicated to serving niche patient populations, particularly those with compromised immune systems.

Flowonix Medical, Inc. is a medical device company focused on developing implantable drug delivery systems to address chronic neurological disorders. The company specializes in creating devices that facilitate the precise infusion of therapeutic drugs directly into the spine, thereby enhancing treatment efficacy for patients experiencing long-term pain. Its product lineup includes the Prometra drug delivery system, which administers Infumorph, a medication designed for pain management, along with the Prometra Pump and a catheter that aids in the accurate placement of medication within the intrathecal space. Established in 2005 and headquartered in Mount Olive, New Jersey, Flowonix also maintains an office in Mansfield, Massachusetts, and is committed to improving patients' quality of life through innovative technology and reliable medical solutions.

Flowonix Medical, Inc. is a medical device company focused on developing implantable drug delivery systems to address chronic neurological disorders. The company specializes in creating devices that facilitate the precise infusion of therapeutic drugs directly into the spine, thereby enhancing treatment efficacy for patients experiencing long-term pain. Its product lineup includes the Prometra drug delivery system, which administers Infumorph, a medication designed for pain management, along with the Prometra Pump and a catheter that aids in the accurate placement of medication within the intrathecal space. Established in 2005 and headquartered in Mount Olive, New Jersey, Flowonix also maintains an office in Mansfield, Massachusetts, and is committed to improving patients' quality of life through innovative technology and reliable medical solutions.

Edge Therapeutics is a clinical-stage biotechnology company based in Berkeley Heights, New Jersey, focused on developing innovative therapies for acute, life-threatening neurological conditions. Established in 2009, the company aims to transform treatment paradigms in hospital settings through its proprietary platform, Precisa, which facilitates the creation of polymer-based therapeutics designed for targeted delivery to injury sites. The lead product candidate, EG-1962, is currently undergoing evaluation in the Phase 3 NEWTON 2 study, aimed at improving outcomes for patients suffering from aneurysmal subarachnoid hemorrhage (aSAH). Additionally, Edge is assessing EG-1964 as a potential prophylactic treatment for chronic subdural hematoma, aimed at preventing recurrent bleeding on the brain's surface. Through these efforts, Edge Therapeutics seeks to address serious unmet medical needs in the field of neurology.

Celator Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company dedicated to developing innovative therapies for cancer treatment. Utilizing its proprietary CombiPlex technology platform, the company designs and evaluates optimized drug combinations that integrate traditional chemotherapies with molecularly targeted agents to enhance anti-cancer efficacy. Notable products in its pipeline include VYXEOS, a nano-scale liposomal formulation of irinotecan and floxuridine, and CPX-351, a liposomal formulation of cytarabine and daunorubicin, both in Phase III clinical trials for acute myeloid leukemia. Additionally, CPX-1, a liposomal formulation of irinotecan and floxuridine, has completed Phase II studies for colorectal cancer. Celator also has a preclinical candidate, CPX-8, which is a hydrophobic docetaxel prodrug nanoparticle formulation. Founded in 1999 and headquartered in Ewing, New Jersey, Celator Pharmaceuticals operates as a subsidiary of Jazz Pharmaceuticals Public Limited Company.

ADMA Biologics, Inc. is a biopharmaceutical company focused on developing, manufacturing, and marketing specialty plasma-derived biologics aimed at treating immune deficiencies and infectious diseases in the United States. The company offers a range of products, including BIVIGAM and ASCENIV, both intravenous immune globulin therapies for primary humoral immunodeficiency, as well as Nabi-HB, which is used for acute exposure to Hepatitis B. ADMA is also involved in the development of additional plasma-derived therapeutics, particularly targeting infections like S. pneumonia. To support its operations, the company runs FDA-licensed source plasma collection facilities known as ADMA BioCenters, which contribute to the supply of plasma necessary for its product manufacturing. ADMA Biologics distributes its products through independent distributors, sales agents, specialty pharmacies, and other healthcare providers. Founded in 2004 and based in Ramsey, New Jersey, ADMA is dedicated to serving niche patient populations, particularly those with compromised immune systems.

ADMA Biologics, Inc. is a biopharmaceutical company focused on developing, manufacturing, and marketing specialty plasma-derived biologics aimed at treating immune deficiencies and infectious diseases in the United States. The company offers a range of products, including BIVIGAM and ASCENIV, both intravenous immune globulin therapies for primary humoral immunodeficiency, as well as Nabi-HB, which is used for acute exposure to Hepatitis B. ADMA is also involved in the development of additional plasma-derived therapeutics, particularly targeting infections like S. pneumonia. To support its operations, the company runs FDA-licensed source plasma collection facilities known as ADMA BioCenters, which contribute to the supply of plasma necessary for its product manufacturing. ADMA Biologics distributes its products through independent distributors, sales agents, specialty pharmacies, and other healthcare providers. Founded in 2004 and based in Ramsey, New Jersey, ADMA is dedicated to serving niche patient populations, particularly those with compromised immune systems.

Prism Career Institute was established in 1986 as a career training school and has since grown to include four locations in New Jersey and Pennsylvania. Each program at the institute is designed to help students get a career-oriented education so they can easily transition into their career after graduation. All programs at Prism Career Institute in Egg Harbor Township last less than a year and train students for a career in some of the most in demand industries today. Prism Career Institute understands that choosing to better your job opportunities by attending school is a big decision. This is why applicants must meet with an Admissions Representative who helps to match them with the program that is best suited for their career goals. Contact Prism Career Institute in Egg Harbor Township today for more information on the admissions process. At Prism Career Institute, students have the option of attending courses full-time or part-time, so those who need to remain employed while attending school have the option to do so. The school works hard to prepare students with all of the skills they will need to transition into their chosen field. Students also graduate from the school equipped with networking and customer service skills to make them more competitive in the job market. Alumni may return to the campus to take classes at no extra charge for up to a year after graduation to refresh any skills they may need. The faculty members at the Prism Career Institute are talented individuals dedicated to passing on knowledge of their field. Most of the faculty are full-time and devote time to getting to know their students. This means that students receive a lot of one-on-one attention, which ensures that nobody is left behind. All faculty members at the school have real-world experience in the profession which they teach. The professors at Prism Career Institute are committed to providing an engaging experience to students and have been locally and nationally recognized for their teaching achievements. Finding the funding to finance your education can be a complicated process. The financial aid staff at Prism Career Institute is committed to helping students navigate through this process. Students who qualify for financial assistance can meet with a staff member from the financial aid office to receive help in completing federal financial aid forms, student loan applications and other forms of financial assistance. For more information on financial aid at Prism Career Institute, contact the school today. Obtaining employment after graduation is the main goal for all students at Prism Career Institute. Although the school cannot guarantee employment, the staff in the career services department is dedicated to providing students with the necessary job searching skills in order to land a job. Students are encouraged to visit the career services department while they are still students at the school to receive professional employment guidance and learn important skills such as resume and cover letter writing. For more information about our graduation rates, the median debt of students who completed the program, and other important information, please visit http://www.prismcareerinstitute.edu/disclosure/ The Cherry Hill and Egg Harbor Twp. campuses are accredited by the Accrediting Commission for Continuing Education and Training (ACCET). NJ campuses are licensed by the NJ Department of Education.

Memory Pharmaceuticals Corp., a biopharmaceutical company, focuses on the discovery and development of drug candidates for the treatment of central nervous system conditions. It offers drugs for neurological diseases associated with aging, such as Alzheimer's disease, as well as psychiatric disorders, such as schizophrenia, cognitive impairment associated with schizophrenia (CIAS), and depression. The company was incorporated in 1997 and is based in Montvale, New Jersey. As of December 31, 2008, Memory Pharmaceuticals Corp. operates as a subsidiary of Hoffmann-La Roche Inc.